medicine, certain targeted drugs may be recognized as more effective in specific subpopulations within a disease. Already, some clinical trials are starting to perform genetic analyses prospectively and we are just now starting to understand the role epigenetics plays in drug metabolism.
DISCLOSURE
VYS is a stock shareholder of Dermveda, has served as a paid advisor for Sanofi, Novartis, SUN Pharma, Pfizer, Menlo Therapeutics, GpSkin, the National Eczema Association, and Global Parents for Eczema Research, is an investigator for AbbVie and Leo Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Active Science.
REFERENCES
- Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244-252.
- Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127-132.
- Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013;169(2):306-313.
- Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc. 2004;1(4):24-29.
- Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis. Curr Med Res Opin. 2016;32(4):721-729.
- Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(5):215-227.
- Keating GM. Apremilast: A review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459-472.
AUTHOR CORRESPONDENCE
Vivian Shi MD vshi@email.arizona.edu
